To influence policy on critical issues like the Priority Review Voucher, biotech CEOs are forming consortiums and going to Washington as a unified group. This collaborative approach is more effective than individual company efforts because it demonstrates a widespread industry problem that needs a legislative solution.

While large pharmaceutical companies spend record amounts lobbying against drug pricing policies, the trade group for smaller biotechs has cut its spending to a 20-year low. This divergence highlights how immediate commercial threats, rather than broader FDA policy changes, are currently driving lobbying priorities for different segments of the industry.

The current political and regulatory environment means running a biotech company is no longer just about science and capital. CEOs must now actively engage in policy discussions and lobby legislators to ensure the ecosystem remains favorable for innovation. Ignoring politics is no longer an option.

Bio is creating a formal system for biotech companies to report challenges with the FDA. Bio will synthesize this feedback monthly and present it directly to FDA leadership, creating a novel channel to elevate systemic issues and improve accountability.

Major pharmaceutical companies are now willing to deploy the "nuclear option" of pulling planned R&D investments to express displeasure with national drug pricing policies. This tactic, seen in the UK, represents a direct and aggressive strategy to pressure governments into accepting higher prices for innovative medicines.

Individual biotech executives are reluctant to publicly challenge the FDA because their companies have drugs under active review. Forming a broad coalition with investors and patient advocates allows them to voice concerns collectively, providing a shield against potential regulatory blowback that any single company might face if it spoke out alone.

To succeed in large pharmaceutical companies, one must operate with a collaborative mindset. Influence is built not by individual discovery, but by working effectively with cross-functional teams (regulatory, commercial, medical affairs) and building trust by focusing on shared goals.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

Despite having previously agreed to individual 'MFN deals,' four major pharmaceutical companies invited to the White House declined to endorse a 90-page bill to codify the policy. This pushback signals a consolidated industry strategy to resist the MFN framework through political and legal channels.